Who is sponsoring NCT06475599?

NCT06475599 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What condition does NCT06475599 study?

NCT06475599 studies Endometrial Cancer.

What drugs are being tested in NCT06475599?

Interventions: Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug.

What is the status of NCT06475599?

NCT06475599 is currently NOT_YET_RECRUITING.

Last reviewed 2024-06-26 · How we verify

Efficacy of Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer in a Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial

NCT06475599 Phase 3 NOT_YET_RECRUITING

To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).

Details

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 3
Status	NOT_YET_RECRUITING
Enrolment	420
Start date	2024-07
Completion	2029-06

Conditions

Endometrial Cancer

Interventions

Anlotinib hydrochloride capsule + TQB2450 injection
Chemotherapy drug

Primary outcomes

Progression-free survival (PFS) assessed by independent imaging review committee (IRC) — Up to 36 months after study start
Progression-free survival (PFS) as assessed by independent imaging review committee (IRC) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST1.1) criteria. Time from subject randomization (first treatment) to first disease progression or death from any cause, whichever occurred first.

Countries

China